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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:
To determine the diagnostic accuracy of transient elastography with CAP for diagnosis of moderate and severe hepatic steatosis in people
with suspected NAFLD when compared with liver biopsy as reference standard. To achieve this, we will compare none/mild hepatic
steatosis (S0 to S1) versus moderate/severe hepatic steatosis (S2 to S3); and none/mild/moderate hepatic steatosis (S0 to S2) versus severe
hepatic steatosis (S3).
Secondary objectives
We aim to also identify the pooled sensitivity and specificity for the most common cut-oH values of CAP for diagnosis of none/mild hepatic
steatosis (S0 to S1) and moderate/severe hepatic steatosis (S2 to S3); or none/mild/moderate hepatic steatosis (S0 to S2) and severe hepatic
steatosis (S3) in people with suspected NAFLD, and to explore potential sources of heterogeneity influencing the diagnostic test accuracy
of CAP (see: Investigations of heterogeneity).
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B A C K G R O U N D
Hepatic steatosis (i.e. abnormal retention of fat) is the main clinical
manifestation of non-alcoholic fatty liver disease (NAFLD) (Tiniakos
2018). Whenever there is a suspicion of NAFLD, hepatic steatosis
should be documented and measured. Steatosis is defined as
intrahepatic fat of at least 5% of liver weight (EASL Guidelines
2016). Liver biopsy has been the primary method for diagnosing
NAFLD, and it is the most accurate method for assessing steatosis
(EASL Guidelines 2016). The assessment of steatosis is based
on measuring the extent of the surface area of a histological
section involved, or uninvolved, in the parenchyma, providing the
percentage of the aHected area. Histologically, hepatic steatosis
is graded from 0 to 3: minimal steatosis (grade S0), defined as
presence of less than 5% or 10%; mild steatosis, between 5% and
33% (grade S1); moderate steatosis, between 33% and 66% (grade
S2); and severe steatosis, more than 66.0% (grade S3) (Table 1).
The pathological spectrum of NAFLD ranges from simple steatosis
to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and
hepatocellular carcinoma (HCC) (Angulo 2002). Diagnosis of
NAFLD is also based on lack of secondary causes of hepatic
fat accumulation: ruling out excessive alcohol consumption,
viral hepatitis, other chronic liver diseases such as Wilson's
disease, haemochromatosis, autoimmune hepatitis, cholestatic
liver disease, starvation, lipodystrophy, coeliac disease, or
Cushing's disease as well as medications (corticosteroids,
methotrexate, diltiazem, oxaliplatin, amiodarone, isoniazid, highly
active antiretroviral therapy, etc.) (Perumpail 2017). Clinical
guidelines suggest moderate consumption of alcohol as a
component of NAFLD diagnosis. In Chalasani 2012, EASL Guidelines
2016, NICE 2016, and AISF 2017 guidelines, it is less than 30 g/
day for men and less than 20 g/day for women; in the American
Association for the Study of Liver Diseases (AASLD) guidelines it is
fewer than 21 standard drinks/week in men and fewer than 14 in
women (Chalasani 2018); and in the Asia-Pacific Guidelines, it is less
than 14 standard alcoholic drinks/week in men and 14 in women
(Chitturi 2018; Wong 2018).
Non-alcoholic hepatic steatosis is associated with obesity, type 2
diabetes mellitus (T2DM), and dyslipidaemia. Most oJen, steatosis
is detected for the first time when an NAFLD is established. There
seems to be no isolated data on the frequency and prognosis of
steatosis. One meta-analysis on data of people with NAFLD from
1989 to 2015 found a global prevalence of 25.2% (Younossi 2016).
Specifically, the prevalence of NAFLD was highest in the Middle
East (31%) and South America (32%), and lowest in Africa (13.5%)
(Younossi 2016).
Among histological features, only liver fibrosis is associated with
long-term outcomes of people with NAFLD (Angulo 2015; Ekstedt
2015). On baseline biopsy, people with NAFLD, but without fibrosis,
exhibited progression of fibrosis of one-stage over 14 years on
average, whereas those with NASH progressed to fibrosis with one
stage over seven years (Singh 2015). McPherson 2015 reported
that progression of NAFLD occurred irrespective of whether the
first biopsy showed hepatic steatosis or NASH; about 20% of
people showed rapid fibrosis, whereas the remaining 80% had
minimal progression. Another study reported that, compared to
the general population, NAFLD was associated with an increased
overall mortality (standardised mortality ratio of 1.34 to 2.6) (Kwak
2015). Adams 2005 and Ekstedt 2006 reported an absolute risk
of liver-related mortality being 1.7% (median follow-up of 8 to
14 years), while Soderberg 2010 reported liver-related mortality
of 9.6% (median follow-up of 21 years). Based on these studies,
Angulo 2013 concluded that "the overall and liver-related mortality
in patients with the whole spectrum of NAFLD is greater than in the
general population of same age and gender, and that complications
of end-stage liver disease contribute significantly to this higher
mortality."
There are no drugs currently approved to prevent or treat
hepatic steatosis. A number of pharmacological interventions have
been tried in NAFLD, but with overall limited benefit. Lifestyle
modification consisting of diet, exercise, and weight loss have been
advocated to treat people with NAFLD. Foregut bariatric surgery
can also be considered an option to specifically treat obese people
with NAFLD or NASH (Chalasani 2018). Traditionally, liver biopsy
has been the primary method for diagnosing and assessing the
severity of NAFLD (EASL Guidelines 2016). However, when a disease
and its progression should be monitored, liver biopsy is not of a
practical use, also because it is an invasive procedure and carries
a small, but definite, risk of complications. Transient elastography
with controlled attenuation parameter (CAP) is an appropriate
alternative to liver biopsy in diagnosing steatosis, identification of
risk groups, and in evaluation of response to lifestyle modifications
(Lombardi 2017; Gurusamy 2018).
Target condition being diagnosed
The target conditions are moderate or severe hepatic steatosis (i.e.
S2 and S3) in people with suspected NAFLD. Moderate steatosis (S2)
is classified by pathology when it is between 33% and 66%, and as
severe (S3) when it is more than 66%.
Index test(s)
Transient elastography with controlled attenuated parameter
Transient elastography with CAP is a suitable diagnostic tool to
detect and quantify steatosis along with measuring liver fibrosis (de
Ledinghen 2014).
Transient elastography is a mechanical test designed to measure
liver stiHness (i.e. the health of the liver) in kilopascals. Steatosis
quantification by CAP analyses a measure of the ultrasound
attenuation, which corresponds to the decrease in amplitude of
ultrasound waves as they propagate through the liver (Echosens
2011). The technology is based on the evaluation of ultrasound
signals acquired using a FibroScan device (an ultrasound-
based vibration-controlled transient elastography (VCTE) system)
(Sandrin 2002). A probe is put on the skin surface overlying the
liver. AJer pressing the button on the probe, a pulse wave is
transmitted across the liver parenchyma. AJer a short interval, a
second ultrasound wave is transmitted, and the diHerence between
the velocity of the two waves in the liver parenchyma is calculated.
Intrahepatic cholestasis, ascites, and congestive heart failure are
factors that can distort the results. VCTE system is contraindicated
for pregnant women and people with active implantable medical
devices (Echosens 2011). CAP is measured with a probe M, designed
for the general adult population, at 3.5 MHz at a depth between
25 mm and 65 mm, or with a probe XL, designed for overweight
people, at a depth between 35 mm and 75 mm. The XL probe was
developed because of problems of obtaining valid measurements
with the M-probe in people with an increased skin-liver length,
which was a frequent finding in obese people (de Ledinghen 2010).
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
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CAP is calculated simultaneously with liver stiHness only if the liver
stiHness measurements are valid (i.e. range between 100 decibel
per metre (dB/m) and 400 dB/m). If they are not valid (i.e. within
the provided range), then CAP is not measured (Echosens 2011).
Measurement confidence is defined as 1. 10 valid measurements
or more; 2. interquartile range/median (IQR/med) less than 30% in
elastography; and 3. success rate greater than 60% (Castera 2010).
The advantages of transient elastography with CAP are that it is a
non-invasive test, easy to perform, provides immediate results, and
has low cost in comparison with other measurement modalities,
such as computed tomography or magnetic resonance-based
methods (de Ledinghen 2014).
One study by Sasso 2010, including 115 participants with chronic
liver disease from various causes, was the first to validate CAP
as a diagnostic tool for detection and quantification of steatosis,
using liver biopsy as the reference standard. Subsequently, strong
correlation of CAP with steatosis in the liver compared with liver
biopsy has been shown for many chronic liver diseases (Table
2). Diagnostic accuracy of transient elastography with CAP may
be aHected by variations in cut-oH values of diHerent steatosis
grades and diHerent covariates (de Ledinghen 2014). Factors
associated with elevated CAP are body mass index (BMI), metabolic
syndrome, alcohol, and liver stiHness (Karlas 2017). Also, accurate
diagnosis of the stage of steatosis makes it possible to evaluate
the risk of developing cardiovascular disease, prognosis, and
eHectiveness of treatment, which in particular can increase the
patient's compliance to further treatment.
Clinical pathway
People with insulin resistance or metabolic risk factors, or both (i.e.
obesity or metabolic syndrome, age more than 50 years) as well as
with persistently abnormal liver enzymes should be suspected of
having NAFLD. International guidelines partly diHer in the diagnosis
of hepatic steatosis in terms of acceptable economic burden (Table
3). The optimal strategy for detecting and grading steatosis, as well
as stratifying people with suspected NAFLD and the way to follow-
up the disease progression, has not yet been established as there
are no pathognomonic symptoms or signs that can be used for the
diagnosis (Leoni 2018).
The non-invasive assessment of steatosis in people with
suspected NAFLD includes clinical, laboratory, and imaging
tests to diagnose NAFLD. A slight increase in the level of
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
or gamma-glutamyl transpeptidase (GGTP) can be observed in
laboratory data, but normal levels of liver enzymes do not
exclude absence of NAFLD. International guidelines vary in their
recommendations on how to confirm the presence of steatosis
and general liver biochemistry in people with suspected NAFLD.
As an initial diagnostic workup, some guidelines recommend
non-invasive imaging examinations, the sequence of which in
practice may depend on the availability and cost (EASL Guidelines
2016; NICE 2016; AISF 2017; Chalasani 2018; Chitturi 2018; Wong
2018). The EASL Guidelines 2016, Asia-Pacific (Chitturi 2018; Wong
2018), and Italian (AISF 2017) clinical guidelines suggest the Fatty
Liver Index (FLI) and the NAFLD liver fat score for assessing the
presence of steatosis. The AASLD guidelines underline the lack of
evidence for the usefulness of quantifying liver steatosis in routine
clinical settings and highlight that only the grade of inflammation
or fibrosis can determine the prognosis of people with NAFLD
(Chalasani 2018). All guidelines previously mentioned agree on
the need of non-invasive laboratory and imaging assessment of
advanced fibrosis as the leading prognostic factor among people
with NAFLD due to a strong correlation with survival rate and liver-
related outcomes. However, histological analysis of liver biopsies
remains the standard against which other methods for assessment
of the presence and amount of hepatic injury due to NAFLD are
measured, especially for detecting NASH (hepatocyte ballooning
and lobular inflammation) and how lobular inflammation diHers
from simple steatosis.
CAP could be used as a non-invasive, inexpensive, and accurate
method to diagnose NAFLD in NAFLD risk groups (de Ledinghen
2014). Asia-Pacific guidelines propose CAP as a useful tool for
diagnosis of NAFLD, as well as for demonstrating improvement
in hepatic steatosis aJer lifestyle intervention and body-weight
reduction (Chitturi 2018; Wong 2018), while other guidelines report
that its role in clinical practice has yet to be determined (Chalasani
2018).
If the diagnostic accuracy of transient elastography plus CAP is
shown to be better than the diagnostic accuracy of abdominal
ultrasound, then it can replace abdominal ultrasound because
transient elastography plus CAP is easier to interpret by
the operator in view of the predefined parameters. Transient
elastography plus CAP may replace liver biopsy, unless results of
liver stiHness and grades of hepatic steatosis measurements are
questionable (Eddowes 2019).
The downstream consequences of testing include the following.
• True-positive (TP): patients would benefit from rapid diagnosis
and refer for an eHective intervention.
• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance and pursuit of an
alternative diagnosis.
• False-positive (FP): patients would probably experience anxiety
and morbidity caused by additional testing, unnecessary
treatment, and possible adverse events; and the chance that a
FP result may halt further diagnostic evaluation.
• False-negative (FN): increased risk of morbidity and mortality
and delayed treatment initiation, lifestyle modifications.
Figure 1 displays a summary of a currently used diagnostic pathway
in assessing the grade of steatosis, choice of intervention, and
monitoring and assessment of treatments.
 
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)









Cochrane Database of Systematic Reviews
Figure 1.   Clinical pathway. NAFLD: non-alcoholic fatty liver disease.
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FLI, NAFLD liver fat score (NAFLD-LFS), hepatic steatosis index (HSI),
visceral adiposity index (VAI), and triglyceride-glucose (TyG) index
are some of the biomarkers most oJen used to quantify steatosis.
They are based on aggregate scores, and diHerent anthropometric
and metabolic parameters. However, their ability to quantify
steatosis is low as shown by one meta-analysis by Fedchuk 2014.
In addition, none of these biomarker tests can distinguish between
moderate and severe steatosis (Fedchuk 2014). The areas under
the receiver-operating-characteristic curves (AUROC) for predicting
steatosis of more than 33% (i.e. moderate and severe) were 0.83
(95% confidence interval (CI) 0.72 to 0.91) for FLI, 0.80 (95% CI
0.69 to 0.88) for NAFLD-LFS, 0.81 (95% CI 0.71 to 0.88) for HSI,
0.92 (95% CI 0.85 to 0.95) for VAI, and 0.90 (0.84 to 0.94) for TyG
indices (Fedchuk 2014). The patient data required to perform the
tests are BMI, waist circumference, triglycerides, gamma-glutamyl
transferase; presence or absence of metabolic syndrome or T2DM,
insulin levels, AST, ALT, high-density lipoprotein cholesterol, and
glucose (Fedchuk 2014).
Other imaging tests
Abdominal ultrasonography is the most common first-line imaging
modality for people with elevated liver enzymes or suspected
NAFLD. As compared to the right kidney parenchyma, distal
attenuation, and the presence of areas of focal sparing, a typical
ultrasonography feature of value to detect or exclude moderate-
to-pronounced fatty infiltration is hyperechogenicity (an increased
response (echo) during the ultrasound examination) (Hernaez
2011). The degree of steatosis can be subjectively scored as
mild, moderate, and severe, or as reported in some studies by
using ordinal ultrasonography scores (Ballestri 2012). In one meta-
analysis by Hernaez 2011, the pooled sensitivity and specificity
of abdominal ultrasonography to distinguish moderate-to-severe
fatty liver from the absence of steatosis, taking liver biopsy
as the reference standard, were 84.8% (95% CI 79.5 to 88.9)
(sensitivity) and 93.6% (95% CI 79.5 to 88.9) (specificity). Abdominal
ultrasonography has limited sensitivity and does not reliably detect
steatosis when it is less than 20% or in people with high BMI
(greater than 40 kg/m2) (EASL Guidelines 2016). It is also operator-
dependent.
Magnetic resonance-based methods are used for the detection
or grading of hepatic steatosis and fibrosis. DiHusion-weighted
magnetic resonance imaging (DW-MRI) measures the random
Brownian motion of water molecules within a voxel of tissue.
Magnetic resonance elastography (MRE) uses shear waves to assess
the tissue displacement in all directions. Magnetic resonance
spectroscopy (MRS) is based on the fact that the distribution of
electrons within an atom causes nuclei in diHerent molecules to
experience slightly diHerent magnetic fields (Tognarelli 2015). DW-
MRI, MRE, and MRS have an overall AUROC of 0.90, sensitivity of
82%, and specificity of 87%. They also exhibit good AUROC (DW-
MRI 0.95 (95% CI 0.93 to 0.97); MRE 0.89 (95% CI 0.86 and 0.91), and
MRS 0.88 (95% CI 0.82 to 0.93) (Wang 2018). Magnetic resonance
imaging proton density fat fraction (MRI-PDFF) of liver tissue is
an imaging biomarker derived from the fat and water component
images acquired during an MRI examination and computed as the
ratio of the fraction of mobile protons belonging to triglyceride,
relative to those to water. According to Gu 2019, the summary
AUROC values of MRI-PDFF for classifying steatosis grades 0 versus
1 to 3 are 0.98, 0 to 1 versus 2 to 3 are 0.91, and 0 to 2 versus 3 are
0.90. All these methods are accurate and fast methods of detecting
liver fat, allowing detailed examination of areas of interest, but they
are expensive and may not be routinely available (Wang 2018; Gu
2019).
Computed tomography can measure tissue density in Hounsfield
units (HU) from air (–1000) at the bottom of the scale, to bone
density at the top of the scale. Computed tomography diagnostic
criteria for steatosis are liver attenuation, at least 10 Hounsfield
Units (HU) less than that of the spleen (sensitivity 60.5% and
specificity 100%), or absolute liver attenuation of less than 40 HU
(sensitivity 52.5% and specificity 100%) (Lawrence 2012).
Rationale
Steatosis generally has a favourable outcome, although people
with isolated hepatic steatosis and with clinical diagnosis of
metabolic syndrome or individual components of metabolic
syndrome may be at risk of more rapidly progressive histological
inflammatory damage and adverse outcomes associated with
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
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NASH (Pais 2013; Rinella 2016). Some studies suggest that the
degree of steatosis may predict the severity of histological features
(Chalasani 2008), and the incidence and prevalence of diabetes
in people with NAFLD (Li 2013; Shah 2015; Targher 2016). The
aggregate data provide strong evidence that people with NAFLD
are at increased 'independent' risk of developing cardiovascular
disease (Armstrong 2014). Similarly, the bidirectional association
between NAFLD and components of metabolic syndrome has
been strongly established. Also, there are established conditions
such as obesity, T2DM, hypertension, and dyslipidaemia, and
emerging conditions, such as sleep apnoea, colorectal cancer,
osteoporosis, psoriasis, endocrinopathies, and polycystic ovary
syndrome independent of obesity, that are associated with NAFLD
(Chalasani 2018). The European Association for the Study of
the Liver recommends diagnosing obese people, people with a
metabolic syndrome, and people at high risk of developing a
cardiovascular disease for presence of NAFLD (EASL Guidelines
2016). The ideal method for evaluation of liver steatosis in people
with suspected NAFLD must be widely available, non-invasive,
safe, sensitive, accurate for quantification, reproducible, and
inexpensive.
The meta-analyses by Shi 2014 and Wang 2015 showed a high
sensitivity and specificity of CAP for NAFLD of S1 or greater,
S2 or greater, and S3 or greater (Table 2). However, the study
authors did not recommend using this method to diagnose liver
steatosis in routine clinical practice. Meta-analyses conducted by
Karlas 2017 and Pu 2019 showed high diagnostic accuracy of
transient elastography with CAP. However, the Pu 2019 meta-
analysis has limitations regarding databases searched and have
flaws in methodology, including lack of risk of bias assessment.
The meta-analysis of individual data by Karlas 2017 included
537 participants, and the meta-analysis by Pu 2019 included
1297 participants. However, there are other relevant studies, not
included in the mentioned meta-analyses.
As researchers are using diHerent cut-oH values to determine the
stage of steatosis in people with NAFLD, we consider it necessary
to conduct this Cochrane systematic review on the diagnostic
accuracy of transient elastography with CAP for diagnosis of
moderate and severe steatosis in people with suspected NAFLD,
including the available evidence.
O B J E C T I V E S
To determine the diagnostic accuracy of transient elastography
with CAP for diagnosis of moderate and severe hepatic steatosis
in people with suspected NAFLD when compared with liver biopsy
as reference standard. To achieve this, we will compare none/
mild hepatic steatosis (S0 to S1) versus moderate/severe hepatic
steatosis (S2 to S3); and none/mild/moderate hepatic steatosis (S0
to S2) versus severe hepatic steatosis (S3).
Secondary objectives
We aim to also identify the pooled sensitivity and specificity for
the most common cut-oH values of CAP for diagnosis of none/mild
hepatic steatosis (S0 to S1) and moderate/severe hepatic steatosis
(S2 to S3); or none/mild/moderate hepatic steatosis (S0 to S2)
and severe hepatic steatosis (S3) in people with suspected NAFLD,
and to explore potential sources of heterogeneity influencing
the diagnostic test accuracy of CAP (see: Investigations of
heterogeneity).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies with liver histology as
reference standard and transient elastography with CAP as index
test, providing diagnostic accuracy data (TP, FP, FN, and TN) in
people with suspected NAFLD. We will include studies irrespective
of publication status, format, and language. We will exclude studies
of case-control design that compared people with known NAFLD to
matched controls. Case-control designs are considered at high risk
of bias, as they inflate accuracy estimates (Colli 2014).
Participants
Study participants can be hospitalised or outpatients, of any
sex and ethnic origin, and at least 18 years old, with suspected
NAFLD. People may present with any diabetes status, and both
secondary causes and a daily alcohol consumption, defined as
more than 30 g/day for men and more than 20 g/day for women,
should be excluded. We will exclude studies with participants who
had previously undergone liver transplantation due to a problem
with the accuracy verifying the aetiology of steatosis. Majority of
people with a long-term survival aJer liver transplantation have
allograJs that are histologically abnormal. This may be caused by
the eHects of immunosuppression or interactions with other graJ
complications (Hubscher 2011).
Index tests
Transient elastography with controlled attenuation parameter
Most oJen, authors use various cut-oH values to grade liver
steatosis: a cut-oH value of 259.4 dB/m to 268 dB/m for S0/S1 versus
S2/S3, and a cut-of value of 280 dB/m to 292.3 dB/m for S0/S2 versus
S3 (Sasso 2010; Karlas 2017). For our review, we will consider the
cut-oH values of transient elastography with CAP as used by the
study authors.
Target conditions
The target conditions will be moderate or severe hepatic steatosis
in people with suspected NAFLD according histopathological
scoring systems for NAFLD (Table 1).
Reference standards
Liver histology with assessment of steatosis.
A liver biopsy allows confirmation of the presence of NAFLD, to
diHerentiate diagnosis between steatosis and steatohepatitis, to
assess the stage of fibrosis, and, based on histological data, to
predict the development of the disease as well as to exclude other
causes of liver damage. However, liver biopsy is not practical when
a disease and its progression needs to be monitored. It is an invasive
procedure and carries a small, but definite risk of complications.
It is also unrealistic to perform liver biopsy in 15% to 40% of the
general population.
Following histological scoring systems, there are four grades of
hepatic steatosis: minimal steatosis (grade 0), defined as presence
of less than 5% or 10%; mild steatosis, between 5% and 33%
(grade 1); moderate steatosis, between 33% and 66% (grade 2);
and severe steatosis, more than 66% (grade 3). The steatohepatitis
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)
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elements are steatosis complicated by liver cell injury (evident
as ballooned hepatocytes, or Mallory hyaline) with substantial
lobular (and occasionally portal) inflammation. The histological
changes characterising the stages of fibrosis are defined as stage
1 (perisinusoidal fibrosis); stage 2 (perisinusoidal fibrosis with
periportal fibrosis); stage 3 (bridging fibrosis); and stage 4 (fully
developed cirrhosis) (Brunt 1999; Kleiner 2012; Bedossa 2014).
DiHerent histopathological scoring systems are used to diagnose
or predict progression of NAFLD (Table 1). The NAFLD activity
score (NAS) evaluates the degree of morphological changes in
scores (Kleiner 2005). It is a modification of the Brunt and Matteoni
scales used earlier in 1999 (Brunt 1999). The SAF (steatosis,
activity, fibrosis) semi-quantitative score, proposed by Bedossa
2014, assesses the severity of NAFLD based on severity of steatosis
(S, steatosis), balloon dystrophy and lobular inflammation (A,
activity), and the stage of liver fibrosis (F, fibrosis). The results of
the SAF score assessments are used as an index for NASH staging
(e.g. S1A2F3, S2A1F1, etc.) (Bedossa 2014). We will use a conversion
grid for hepatic fibrosis staging if a study assesses fibrosis according
to Metavir, Kleiner, or Ishak score (French METAVIR CSG 1994: Ishak
1995; Kleiner 2005; Table 4). We will add other histopathological
scoring systems to Table 4 if such are used in the included studies.
Search methods for identification of studies
We will combine electronic searches with reading references of the
identified studies of possible interest. We will include all studies
irrespective of language of publication and publication status.
We will translate non-English language articles with the help of
Cochrane Hepato-Biliary Group (CHBG) collaborators.
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (maintained and searched internally by the
CHBG Information Specialist via the Cochrane Register of
Studies Web), the Cochrane Hepato-Biliary Group Diagnostic
Test Accuracy Studies Register (maintained and searched
internally by the CHBG Information Specialist via the Cochrane
Register of Studies Web), the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid), CINAHL
(EBSCOhost), LILACS (Bireme), Science Citation Index Expanded
(Web of Science), and Conference Proceedings Citation Index
– Science (Web of Science) (Royle 2003). We will also search
ClinicalTrial.gov (clinicaltrials.gov/), European Medicines Agency
(EMA) (www.ema.europa.eu/ema/), World Health Organization
International Clinical Trial Registry Platform (www.who.int/ictrp),
and the Food and Drug Administration (FDA) (www.fda.gov).
Appendix 1 shows the preliminary search strategies for the diHerent
databases with the expected time spans for the searches. The given
search strategies may be improved at the review preparation phase.
Searching other resources
We will search the references of the included studies to identify
additional studies. We will also search for articles related to the
included studies by performing the ’related search’ function in
MEDLINE (OvidSP) and Embase (OvidSP) and a 'citing reference'
search (by searching the articles that cite the included articles)
in these databases. We will also search for other types of grey
literature in the System for Information on Grey Literature in Europe
OpenGrey (www.opengrey.eu/).
Data collection and analysis
We will follow available guidelines as provided in the Cochrane
Handbook for Diagnostic Test of Accuracy Reviews (DTA Handbook
2013).
Selection of studies
Three review authors (TT, AB, and CP) will independently identify
relevant studies from the retrieved references. The first selection
will be based on reference title or abstract. For the second selection,
we will retrieve the full texts of selected studies considered to be
relevant by at least one of the review authors. Two review authors
will independently screen the full-text of the publications against
the inclusion criteria and will resolve any diHerences through
discussion. We will remove duplicates and list multiple publications
of the same study within its main reference. We will record the
number and details of all studies not fulfilling the inclusion criteria,
based on full-text assessment in the 'Characteristics of excluded
studies' table, with the reasons for exclusion. We will illustrate
the study selection process using a PRISMA diagram (Moher 2011).
We will solve disagreements through discussion. If disagreements
persist, AS or KSG will serve as arbitrator.
Data extraction and management
Three review authors (TT, AB, and CP) will independently extract
data from each included study, using a prepiloted data extraction
form by TT (Table 5). We will then compare our data extraction, and
we will resolve diHerences by discussion.
We will extract all necessary data to calculate TP, FP, TN, and
FN values, using the reference standard of liver histology. We will
summarise the data from each study in 2 × 2 tables (TP, FP, FN,
TN), according to the index tests considered. We will use Review
Manager 5 soJware to enter data and perform analyses (Review
Manager 2014). If information on any of the TP, FP, FN, and TN
diagnostic test values or results are missing, we will attempt to
derive these using other information that the study may provide.
Missing data
We will contact primary authors of abstract publications and full-
text publications by e-mail to ask for missing data which are needed
to design the 2 × 2 tables. If we receive no reply, we will send a
second e-mail aJer two weeks. If no reply is received, then we will
list the study in 'Excluded studies', with a reason for exclusion.
In case a full-text publication of a study, presented only in an
abstract format, is not found, and the abstract lacks the data
we need, and study authors do not respond to our requests for
missing data, we will judge if we shall list the abstract publication
within 'Excluded studies' or 'Studies awaiting assessment', in view
of future update of the review.
Assessment of methodological quality
We will use the QUADAS-2 (QUality Assessment of Diagnostic
Accuracy Studies) tool, to assess risk of bias in diagnostic test
accuracy studies and the applicability of their results. QUADAS-2
is based on four quality domains: participant selection, index
test, reference standard, and flow and timing (Whiting 2011;
QUADAS-2). There are signalling questions for each of the domains,
used to make judgements in terms of risk of bias. The answers
to the signalling questions are 'yes', 'no', or 'unclear'. The first
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three domains are also judged in terms of concerns regarding
applicability, and the answers can be 'low', 'high', or 'unclear'.
Appendix 2 shows the signalling questions to our review subject,
and the criteria that we will use to assess the methodological
quality of each study in our review. Regarding the 'flow and timing'
domain, we will consider an interval of three months (12 weeks)
the most appropriate interval between the reference standard
test and the index test. However, in studies where participants
underwent bariatric surgery, we will consider an interval of one
month (four weeks) the most appropriate interval between the
reference standard test and the index test. This is due to data that
have shown a significant decrease in steatosis three months aJer
bariatric surgery (Aldoheyan 2017).
Two review authors (TT and AB) will independently judge risk of
bias in each domain and applicability of results. They will provide
quotes and comments to support each judgement for each domain.
In case of discrepancies and no agreement reached, a third author
(CP or KSG) will act as arbitrator.
If we judge a study as 'low' on all domains relating to bias or
applicability, then our overall judgement for that study will be 'low
risk of bias' or 'low concern regarding applicability'. If we judge a
study as 'high' or 'unclear' in one or more domains relating to bias
or applicability, then our overall judgement for that study will be 'at
risk of bias' or as having 'concerns regarding applicability'.
The guidance to arrive at judgements for risk of bias in each study
domain is provided in Appendix 2.
Two review authors (TT and AB) will present the results in 'Risk of
bias' summaries and graphs in addition to a narrative summary,
as advised on the QUADAS-2 website. We will check the QUADAS-2
website for possible updates during the review preparation.
Statistical analysis and data synthesis
We will carry out statistical analyses according to
recommendations provided in the Cochrane Handbook for
Systematic Reviews of Diagnostic Test Accuracy (Macaskill 2010;
DTA Handbook 2013). The analyses will be performed using Review
Manager 5 (Review Manager 2014) and Stata Statistical SoJware
(Release 16. TX: StataCorp LLC).
We will build 2 × 2 tables of CAP performance (TP, TN, FP, FN)
for all of the predefined target conditions (moderate and severe
steatosis). We will estimate sensitivity, specificity, and positive
and negative likelihood ratios (LR+ and LR-) with their 95% CIs.
Summary LR+ and LR- will be calculated as part of the METADAS
code using the formula LR+ = sensitivity/(1 – specificity) and
LR– = (1 – specificity)/sensitivity (DTA Handbook 2013). First,
we will perform a graphical descriptive analysis of the included
studies: we will present coupled forest plots of sensitivity and
specificity separately, with their 95% CIs, and we will provide a
graphical representation of the studies in the receiver operating
characteristic (ROC) space (sensitivity against 1 – specificity).
Second, where appropriate, we will perform meta-analyses. The
method that we will use to estimate summary statistic will depend
on the variability in positivity thresholds. If the primary studies
report accuracy estimates of CAP using diHerent cut-oH values, we
will use the hierarchical summary ROC model (HSROC) to pool data
(sensitivities and specificities) and to estimate the summary ROC
(SROC) curve (Macaskill 2010).
If performance reported across the primary studies is based on
consistent cut-oH values, we will use the bivariate model, and we
will provide estimates of summary sensitivity and specificity.
For primary studies that report accuracy results for more than one
cut-oH value, we will report sensitivities and specificities for all of
the cut-oH values, but we will use a single cut-oH value of CAP for
each study in HSROC analysis. This value will be the most frequently
used cut-oH value.
We do not plan to include non-evaluable index test results in
our main statistical analysis. We plan to perform an 'intention-
to-diagnose' analysis as an additional sensitivity analysis (See
Sensitivity analyses). We will classify participants with non-
evaluable index test results as FPs if they had a negative reference
standard or FNs with a positive reference standard (Schuetz 2012).
We will use 3 × 2 tables. If data for the intention-to-diagnose
analyses are not retrievable from the text, and as mentioned earlier,
we will contact publication authors. If we receive no reply, we will
include the study in the analyses with data retrievable from the
published manuscript.
We will rate the certainty of the evidence, and we will present
a summary of our findings, using the GRADE approach (GRADE
Handbook 2013; GRADEpro GDT) (detailed below).
Investigations of heterogeneity
We plan to investigate if the following potential sources of
heterogeneity may influence our overall results.
• As there is a significant variation in the activity of steatohepatitis
and liver fibrosis among patients, we will analyse:
* the diHerent levels of histological activity (from 0 to 4):
studies including more than 50% of participants with the sum
of ballooning and lobular inflammation below 2 compared
to studies including more than 50% of participants with 2 or
greater grades of activity – categorical covariate;
* the diHerent serum levels of ALT activity (increased ALT
activity will be defined as serum ALT above the upper limit
of normal, that is, more than 40 IU/L (Gawrieh 2019)): studies
including more than 50% of participants with normal serum
levels of ALT compared to studies including more than 50% of
participants with serum levels of ALT greater than the upper
limit – categorical covariate;
* the diHerent levels of liver stiHness, in kilopascals (studies
including more than 50% of participants with F0/F1/F2 with a
cut-oH 8.8 kPa compared to studies including more than 50%
of participants with F2/F3 with a cut-oH 12.0 kPa compared
to studies including more than 50% of participants with
F3/F4 with a cut-oH 38.6 kPa (Boursier 2016)) – categorical
covariate;
* the diHerent levels of histological fibrosis stage (studies
including more than 50% of participants with F0/F1/F2
compared to studies including more than 50% of participants
with F3/F4 (Table 4)) – categorical covariate.
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• As T2DM is associated with the development of NAFLD and can
lead to advanced stages, we will analyse:
* studies including more than 50% of participants with T2DM
compared to studies including more than 50% of participants
without T2DM (a categorical covariate).
• As the presence and severity of obesity may limit the obtaining
of reliable CAP measurements and requires the use of XL probe,
we will analyse:
* the diHerent BMIs; studies including more than 50% of
participants with BMI below 25 kg/m2 compared to studies
including more than 50% of participants with BMI 25 kg/m2
or more) (a categorical covariate);
* the diHerent probes for measuring CAP: studies including
more than 50% of participants with M probe or studies
including more than 50% of participants with XL probe (a
categorical covariate).
• As there are diHerences in epidemiology of NAFLD in continents
and subcontinents, we will analyse:
* the study location (population diHerences): European
compared to Asia compared to Africa compared to America
(Northern America compared to South America, if relevant
studies will be found) (a categorical covariate).
We will estimate eHects by adding covariates to the bivariate or
HSROC model (depending on the model chosen based on the
variation in positivity thresholds reported in the studies). We will
assess the statistical significance of the covariate eHect using the
log-likelihood ratio test for comparison of models with and without
the covariate term. We will consider a P less than 0.05 as two-sided
and statistically significant.
Sensitivity analyses
We will perform sensitivity analysis by excluding studies:
• at high risk of bias, that is, studies having high risk of bias in at
least one of the domains of QUADAS-2 (Appendix 2);
• published only in abstract or letter form;
• with 'no' or 'unclear' answer to the signalling questions: "If
a threshold was used, was it prespecified?", "Was there an
appropriate interval between the index test and the reference
standard?"
• with 'no' or 'unclear' answer to the signalling question: "Was
there an appropriate interval between the index test and the
reference standard?"
• intention-to-diagnose analyses in terms of index test results
(Schuetz 2012).
Publication bias: we will rate publication bias as undetected (not
serious) because of the comprehensiveness of the literature search
and following extensive outreach to researchers to identify studies.
Certainty of the evidence and 'Summary of findings' table
We will consider the following GRADE factors to assess the certainty
of the evidence:
• risk of bias: we will use QUADAS-2 to assess risk of bias;
• indirectness: for the review questions, we will look for important
diHerences between the populations studied (e.g. the spectrum
of disease), the setting, the index test, and the reference
standard;
• inconsistency: we will carry out prespecified analyses to
investigate potential sources of heterogeneity, and we will
downgrade the evidence when we cannot explain inconsistency
in the accuracy estimates;
• imprecision: we will look at the CIs of sensitivity and specificity
estimates and at the unexplained heterogeneity of the results;
or TP, FP, FN, and TN rates;
• publication bias: we will use the trim-and-fill method
(Schünemann 2020).
We will follow the instructions in Section 7.5. 'Judgment about the
quality of the underlying evidence' of the GRADE Handbook 2013
on how to downgrade or upgrade the evidence. We will justify all
our decisions, using footnotes, and we will make comments to aid
reader's understanding of the review, where necessary.
We will prepare a 'Summary of Findings' table to present the
main results and key information regarding our assessment of
the certainty of evidence, using the GRADE approach (GRADE
Handbook 2013; GRADEpro GDT).
We will rate the certainty of the evidence in one of the four
grades: high, moderate, low, or very low, defined as follows (GRADE
Handbook 2013; GRADEpro GDT).
• High: we are very confident that the true eHect lies close to that
of the eHect estimate.
• Moderate: we are moderately confident of the eHect estimate
and that the true eHect is likely to be close to the eHect estimate,
but there is a possibility that it is substantially diHerent.
• Low: our confidence in the eHect estimate is limited, such that
the true eHect may be substantially diHerent from the eHect
estimate.
• Very low: we have very little confidence in the eHect estimate,
such that the true eHect is likely to be substantially diHerent
from the estimate of eHect.
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Brunt 1999 NAS (Kleiner 2005) plus fi-
brosis
SAF* (Bedossa 2014)
S0 0–10% 0–5% 0–5%





S2 34–66% 34–66% 34–66%
Table 1.   Conversion grid: histopathological scoring systems for NAFLD 
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of foci of inflam-
matory cells with-
in the lobule) 1
> 4 > 4
> 2
0 None/minimal None Normal hepatocytes
1 Present—zone 3 Few Clusters of hepatocytes of normal size,




2 Marked—zone 3 Many Same as grade 1 with some enlarged he-
patocytes, at least 2-fold that of normal
cells
F0 None None None
F1 Perisinusoidal or
portal fibrosis
1: perisinusoidal or periportal
1A: mild, zone 3, perisinusoidal
1B: moderate, zone 3, perisi-
nusoidal
1C: portal/periportal






Perisinusoidal and periportal fibrosis
without bridging
F3 Bridging fibrosis Bridging fibrosis Bridging fibrosis
Fibrosis
F4 Cirrhosis Cirrhosis Cirrhosis
Table 1.   Conversion grid: histopathological scoring systems for NAFLD  (Continued)
NAS: NAFLD activity score; SAF: steatosis, activity, fibrosis.
 
 








S1 (mild steatosis) 237.7 dB/m 232.5 dB/m 238 dB/m and 250 dB/m 248 dB/m
SE 0.91 0.78 0.78 0.688
SP 0.81 0.79 0.79 0.822
S2 (moderate steatosis) 259.4 dB/m 255 dB/m 259 dB/m and 263 dB/m 268 dB/m
SE 0.89 0.85 0.82 0.773
SP 0.86 0.79 0.79 0.812
Table 2.   Controlled attenuation parameter staging and proposed values 
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)
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S3 (severe steatosis) 292.3 dB/m 290 dB/m 290 dB/m 280 dB/m
SE 1 0.83 0.86 0.882
SP 0.78 0.79 0.89 0.776
Table 2.   Controlled attenuation parameter staging and proposed values  (Continued)
S1: mild steatosis (5% or 10% to 33% (depending on scale used)); S2: moderate steatosis (34% to 66%); S3: severe steatosis (greater than
66%) (Index test(s)) (Table 1); SE: sensitivity; SP: specificity; dB/m: decibel/milliwatt.
 
 
  EASL NICE Asia-Pacific AISF AASLD
Systematic diagnosis of
NAFLD
No No No No No















for people with type 2 diabetes
mellitus.
Table 3.   Comparative analysis of recommendations for the diagnosis of non-alcoholic fatty liver disease 
AASLD: American Association for the Study of Liver Diseases (Chalasani 2018); Asia-Pacific: Asia-Pacific Working Party (Chitturi 2018; Wong
2018); AISF: Italian Association for the Study of the Liver (AISF 2017); EASL: European Association for the Study of the Liver (EASL Guidelines
2016); NICE: National Institute for Health and Care Excellence (NICE 2016).
 
 
Stage of estimated fibrosis following:








Table 4.   Semi-quantitative histopathological scoring systems for progression of fibrosis to cirrhosis. Conversion
grid for the stages of hepatic fibrosis 
F: stage of hepatic fibrosis; F0: no fibrosis; F1: portal fibrous expansion; F2: thin fibrous septa emanating from portal triads; F3: fibrous septa
bridging portal triads and central veins; F4: cirrhosis. Clinically significant fibrosis is generally defined as F2 or greater (on the METAVIR
scale from F0 to F4 with F4 being cirrhosis).
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Start and finish dates of study
Study characteristics
Study location (country)
Number of participants meeting the criteria
Total number of participants assessed
Age distribution (mean/median, standard deviation, range)
Sex distribution
Study location
Presence or absence of diabetes mellitus




Type of index test's probe used (M or XL)
Cut-oH level used for staging of steatosis, dB/m
Blinding of operators for results of histopathological analysis
The validity of the measurements (Number of valid measurements
Success rate, IQR/med)
Levels of liver stiffness, kPa
Index test
Missing results for index test
Blinding of pathologists to results of TE with CAP
Severity of steatosis, %
Missing results for reference standard
Reference test
Levels of histological activity (from 0 to 4)
Table 5.   Data extraction form 
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)









Cochrane Database of Systematic Reviews
Flow and timing Time interval between index test(s) and reference test (weeks)
True positives for each presented cut-oH value
False positives for each presented cut-oH value
True negatives for each presented cut-oH value
Study results
False negatives for each presented cut-oH value
Correspondence with authors  
Funding Source of funding
Are study authors affiliated with the manufacturer of the index test?
Is the study directly funded by the manufacturer?
Have study authors reported conflicts of interests related to the manufacturer or other funding
sources?
Table 5.   Data extraction form  (Continued)
BMI: body mass index; dB/m: decibel/milliwatt; IQR/med: interquartile range/median: kPa: kilopascal; TE with CAP: transient elastography
with controlled attenuation parameter.
 
 
A P P E N D I C E S
Appendix 1. Search strategy
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
non-alcoholic fatty liver disease
 




Date will be given at
review stage.
(elastogra* or elastic* or TE or fibroscan* or VCTE or controlled attenuation para-
met* or CAP) and (fibro* or cirrho* or steatohepati* or steatos* or (nonalcoholic




agnostic Test of Ac-
curacy Studies Regis-
ter
Date will be given at
review stage.
(elastogra* or elastic* or TE or fibroscan* or VCTE or controlled attenuation para-
met* or CAP) and (fibro* or cirrho* or steatohepati* or steatos* or (nonalcoholic







Latest issue #1 MeSH descriptor: [Elasticity Imaging Techniques] explode all trees
#2 MeSH descriptor: [Liver] explode all trees and with qualifier(s): [diagnostic imag-
ing - DG]
#3 elastogra* or elastic* or TE or fibroscan* or VCTE
#4 controlled attenuation paramet* or CAP
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Non-alcoholic Fatty Liver Disease] explode all trees
 
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)
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#7 MeSH descriptor: [Fatty Liver] explode all trees
#8 MeSH descriptor: [Liver Cirrhosis] explode all trees
#9 MeSH descriptor: [Fibrosis] explode all trees
#10 (fibro* or cirrho* or steatohepati* or steatos* or non?alcoholic near fatty or
NAFL* or NASH)
#11 #6 or #7 or #8 or #9 or #10
#12 #5 and #11
MEDLINE Ovid 1946 to the date of
the search
1. exp Elasticity Imaging Techniques/
2. exp Liver/dg [Diagnostic Imaging]
3. (elastogra* or elastic* or TE or fibroscan* or VCTE).mp. [mp=title, abstract, origi-
nal title, name of substance word, subject heading word, floating sub-heading word,
keyword heading word, organism supplementary concept word, protocol supple-
mentary concept word, rare disease supplementary concept word, unique identifi-
er, synonyms]
4. (controlled attenuation paramet* or CAP).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, key-
word heading word, organism supplementary concept word, protocol supplemen-
tary concept word, rare disease supplementary concept word, unique identifier,
synonyms]
5. 1 or 2 or 3 or 4
6. exp Non-alcoholic Fatty Liver Disease/
7. exp Fatty Liver/
8. exp Liver Cirrhosis/
9. exp Fibrosis/
10. (fibro* or cirrho* or steatohepati* or steatos* or (non?alcoholic adj fatty) or
NAFL* or NASH).mp. [mp=title, abstract, original title, name of substance word, sub-
ject heading word, floating sub-heading word, keyword heading word, organism
supplementary concept word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier, synonyms]
11. 6 or 7 or 8 or 9 or 10
12. 5 and 11
13. limit 12 to ("adolescent (13 to 18 years)" or "young adult (19 to 24 years)" or
"adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age
(45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged
(80 and over)")
Embase Ovid 1974 to the date of
the search
1. exp transient elastography/
2. exp elastograph/
3. (elastogra* or elastic* or TE or fibroscan* or VCTE).mp. [mp=title, abstract, head-
ing word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword, floating subheading word, candidate term word]
4. (controlled attenuation paramet* or CAP).mp. [mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word, candidate term word]
  (Continued)
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)
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5. 1 or 2 or 3 or 4
6. exp nonalcoholic fatty liver/
7. exp fatty liver/
8. exp liver cirrhosis/
9. exp liver fibrosis/
10. (fibro* or cirrho* or steatohepati* or steatos* or (non?alcoholic adj fatty) or
NAFL* or NASH).mp. [mp=title, abstract, heading word, drug trade name, original ti-
tle, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word, candidate term word]
11. 6 or 7 or 8 or 9 or 10
12. 5 and 11
13. limit 12 to (adult <18 to 64 years> or aged <65+ years>)
LILACS (Bireme) 1982 to the date of
the search
elastogra$ or elastic$ or TE or fibroscan$ or VCTE [Words] and (fibro$ or cirrho$ or




1900 to the date of
the search
#3 #2 AND #1
#2 TI=(fibro* or cirrho* or steatohepati* or steatos* or (non?alcoholic near fatty) or
NAFL* or NASH)




– Science (Web of
Science)
1990 to the date of
the search
#3 #2 AND #1
#2 TI=(fibro* or cirrho* or steatohepati* or steatos* or (non?alcoholic near fatty) or
NAFL* or NASH)












Q1: "Was a consecutive or
random sample of partici-
pants enrolled?"
Yes – If the study reports
on a consecutive or a ran-
dom selection of partici-
pants.
No – if the study reports
on another form of selec-
tion of participants.
Q1: "Were the index test re-
sults interpreted without
knowledge of the results of
the reference standard?"
Yes – if the study reports
that the results of the index
test were interpreted with-
out the knowledge of the re-
sults of the reference stan-
dard.
No – if the study reports
that results of the index
test were interpreted with
Q1: "Is the reference stan-
dard likely to correctly clas-
sify the target condition?"
Yes – this item will always
be 'Yes' because a correct
reference standard is part of
the inclusion criteria of this
review.
No – not applicable.
Unclear – not applicable.
Q1: "Was there an appro-
priate interval between the
index test and the refer-
ence standard?"
Yes – if the interval be-
tween the index test and
the reference standard
was < 3 months.
No – if the interval was > 3
months.
Unclear – if the study does
not report the interval be-
 
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
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Unclear – if the study does
not report on how the par-
ticipants were enrolled.
Q2: "Did the study avoid in-
appropriate exclusions?"
Yes – if definitions of exclu-
sion criteria are inappro-
priate (e.g. difficult to di-
agnose participants, fail-
ure at liver biopsy, failure
on transient elastography
with controlled attenua-
tion parameter) and all ex-
clusions are reported.
No – if exclusion criteria
are inappropriate and ex-
clusions are not reported.
Unclear – if the study does
not report causes of exclu-
sions.
the results of the reference
standard.
Unclear – if the study does
not report information
about blinding of the results
of the index test and refer-
ence standard.
Q2: "If a threshold was used,
was it prespecified?"
Yes – the cut-oH of tran-
sient elastography with
controlled attenuation pa-
rameter for specific steato-
sis stage was prespecified.
No – it was not.
Unclear – there was no such
information.
Q2: "Were the results of liver
biopsy interpreted without




Yes – if the study reports
that the results of the refer-
ence standard were inter-
preted without the knowl-
edge of the results of the in-
dex test.
No – if the study reports
that the results of the refer-
ence standard were inter-
preted with the knowledge
of the results of the index
test.
Unclear – if the study does
not report information
about blinding of the results
of the reference standard
and the index test.
tween the index test and
the reference standard.
For studies with bariatric
interventions:
Yes – if the interval be-
tween the index test and
the reference standard
was ≤ 1 month.
No – if the interval was > 1
month.
Unclear – if the study does
not report the interval be-
tween the index test and
the reference standard.
Q2: "Did all participants re-
ceive the same reference
standard (liver biopsy)?"
Yes – if the study has on-
ly 1 reference standard for
all the participants
No – if the study has > 1
reference standard.
Unclear – if the study in-
formation regarding the
use of reference standard
are unclear
Q3: "Were all participants
included in the analysis
and analysed according to
intention-to-diagnose prin-
ciple (non-evaluable re-
sults considered as false)?"
Yes – if all enrolled partici-
pants were included in the
analysis and non-evalu-




No – if any participant was
excluded from the analy-
sis for any reason or non-
evaluable index test re-
sults were not analysed
according to intention-to-
diagnose principle.
Unclear – if the exclusion
of participants from the
analysis is unclear.
  (Continued)
Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with
suspected non-alcoholic fatty liver disease (Protocol)









Cochrane Database of Systematic Reviews
Risk of
bias
Could the selection of par-
ticipants have introduced
bias?
Low risk: 'Yes' for all sig-
nalling questions.
High risk: 'No' or 'Unclear'
for ≥ 1 signalling question.
Could the conduct or inter-
pretation of the index test
have introduced bias?
Low risk: 'Yes' for all sig-
nalling questions.
High risk: 'No' or 'Unclear'
for ≥ 1 signalling question.
Could the reference stan-
dard, its conduct, or its inter-
pretation have introduced
bias?
Low risk: 'Yes' for all sig-
nalling questions.
High risk: 'No' or 'Unclear'
for ≥ 1 signalling question.
Could the participant flow
have introduced bias?
Low risk: 'Yes' for all sig-
nalling questions.
High risk: 'No' or 'Unclear'





Are there concerns that in-
cluded participants and
setting do not match the
review question?
Low concern: there was
low concern that the in-
cluded participants did
not match the review
question.
High concern: there was
high concern that the in-
cluded participants did
not match the review
question.
Unclear concern: if it was
unclear.
Are there concerns that the
index test, its conduct, or in-
terpretation differ from the
review question?
Low concern: the index test,
its conduct, or its interpre-
tation does not differ from
the way it is used in clinical
practice.
High concern: the index
test, its conduct, or its in-
terpretation differs from
the way it is used in clinical
practice.
Unclear concern: if it was
unclear.
Are there concerns that the
target condition as defined
by the reference standard
does not match the ques-
tion?
High concern: all partici-
pants did not undergo liver
biopsy for steatosis.
Low concern: all partici-
pants underwent liver biop-
sy for steatosis.












• If we answered all signalling questions for a domain 'yes', then we will judge risk of bias
as 'low'.
• If we answered all or most signalling questions for a domain 'no', then we will judge risk
of bias as 'high'.
• If we answered only 1 signalling question for a domain 'no', we will discuss further the
risk of bias judgement.
• If we answered all or most signalling questions for a domain 'unclear', then we will judge
risk of bias as 'unclear'.
• If we answered only 1 signalling question for a domain 'unclear', we will discuss further
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